81 filings
6-K
OKYO
OKYO Pharma Ltd
8 May 24
OKYO Pharma Announces Participation in May 2024 Investor Conferences
7:00am
6-K
OKYO
OKYO Pharma Ltd
30 Apr 24
Current report (foreign)
7:00am
6-K
OKYO
OKYO Pharma Ltd
8 Apr 24
Current report (foreign)
7:00pm
6-K
OKYO
OKYO Pharma Ltd
4 Apr 24
Current report (foreign)
6:30am
6-K
OKYO
OKYO Pharma Ltd
2 Apr 24
Current report (foreign)
7:00am
6-K
p4t7fn
29 Mar 24
Current report (foreign)
2:30pm
6-K
czrzdg59nto5hwjp1apk
22 Mar 24
Current report (foreign)
7:00am
6-K
j20z54bvo48 6lw9vby
21 Mar 24
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
7:00am
6-K
b1vkjv1ov 0ejm4j7evh
20 Mar 24
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
8:07am
6-K
m6qm65 73nxhib2obu
9 Feb 24
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
7:00am
6-K
4w5 kv52y2hkjm
31 Jan 24
Current report (foreign)
7:00am
6-K
m4piwvd7u4xgq0ll35o
8 Jan 24
Current report (foreign)
7:00am
6-K
003 4dlgfwbk
5 Jan 24
Current report (foreign)
9:30am
6-K
ts26bv9qzw69nq
21 Dec 23
Current report (foreign)
7:35am
6-K
v7cywqcfqo
18 Dec 23
Current report (foreign)
4:56pm
6-K
byxbbj c9j2bet6etu5r
4 Dec 23
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
7:00am
6-K
dxrfrb
29 Nov 23
Current report (foreign)
7:00am
6-K
9dqjy6tg
1 Nov 23
Current report (foreign)
4:55pm
6-K
e177ndw7567jrh9
31 Oct 23
OKYO Pharma Announces $5.84 Million cash raise and payables reduction
7:00am
6-K
wi6e01v6n8u
10 Oct 23
Current report (foreign)
7:00am